D. Vijay Pharma Private Limited
D. Vijay Pharma Private Limited
Send Email
0804895547976% Response Rate
Search

Home » Our Products » Oncology Drugs


Oncology Drugs

 

Zoladex 3.6mg Injection Astra Zeneca

REQUEST CALLBACK

Zoladex 3.6mg Injection Astra Zeneca
  • Zoladex 3.6mg Injection Astra Zeneca
  • Zoladex 3.6mg Injection Astra Zeneca
  • Zoladex 3.6mg Injection Astra Zeneca
  • +7 Zoladex 3.6mg Injection Astra Zeneca
Get Best Quote

Thanks for Contacting Us.

Approx. Rs 5,900 / VialGet Latest Price

Product Details:
UsageHospital
Form of MedicineInjection
Available Dose3.6,10.8 mg
CompositionGoserelin Acetate Depot Injection
BrandAstra Zeneca

Zoladex is used in men to treat symptoms of prostate cancer, and in women to treat breast cancer or endometriosis. Zoladex is also used in women to prepare the lining of the uterus for endometrial ablation (a surgery to correct abnormal uterine bleeding.

Each Prefilled Injection contains:
  • Goserelin acetate equivalent to Goserelin Ph. eur. 10.8 mg Peptide base in a long acting sustained release depot

Additional Information:

  • Item Code: 9164
  • Pay Mode Terms: L/C (Letter of Credit),T/T (Bank Transfer),D/P
  • Port of Dispatch: Mumbai, NASHIK , India
  • Packaging Details: Room Temperature Product
  • Yes! I am interested

    Themiseal Solution

    REQUEST CALLBACK

    Themiseal Solution
    • Themiseal Solution
    • Themiseal Solution
    • Themiseal Solution
    Get Best Quote

    Thanks for Contacting Us.

    Approx. Rs 320 / LitreGet Latest Price

    Product Details:
    Minimum Order Quantity1 Litre
    Packaging Size100 ML
    FormLiquid
    Usage/ApplicationProtection From Infection
    TypeLiquid
    Packaging TypeBottle
    Size90 Ml
    MaterialAntiseptic Solution
    FeatureFeracrylum

    A wound is a loss or breaking of cellular and anatomic or functional continuity of living tissue under the action of any external agency, including surgery (Patil et. Al., 2001). In this general definition many subdivisions are possible, taking into account and grouping together the various forms of violence or tissue damage. Destruction of skin by a burn or a trauma can cause severe loss of the very important protective functions of skin. This may result into functional interferences or even fatal manifestation in serious cases. Therefore, it is required that the process of wound healing should be executed immediately after the initiation of a wound. The process of wound healing primarily involves an acute inflammatory phase, collagen and other macromolecular synthesis, tissue remodeling and finally scar formation (Chithra et. Al., 1998) This process is primarily characterized by three mechanisms. In each wound one of the three mechanisms predominates. The three mechanisms of wound healing are contraction, Epithelialization, and connective tissue deposition. The main stages of healing are (1) Inflammation (2) Proliferation and repair (3) Remodeling (Del Maestra, 1984). In each of these stages, specific components play a part through several mediators. However, with respect to gross morphological changes a thin liner red scar is formed at first which is raised above the level of the surrounding skin but this gradually fades until it is considerable paler than the surrounding skin. For many weeks after the scar forms, the process of contracture continues as is observed by the gradual shortening of the wound.

    It has been reported that wound healing is more efficient under moist wound environment. Hence, currently a treatment encompassing of the application of gel/cream based synthetic/natural agents in and around the wound area is preferred. A typical treatment encompasses of cleaning the wound are with any antiseptic compound and then application of a wound healing agent that quickens the pace of natural wound closure. Such an agent may be a synthetic or herbal compound with established activity (Patil et. Al., 2001; Shirwarkar et. Al., 2003; Fulzele al. 2003) In this paper the wound healing activity of a formulation has been studied. MATERIAL AND METHODS The 3% Hemolok gel used was acquired from Themis Medicare Limited, Mumbai. 5% Povidone iodine solution w/v made by ICI India Limited was diluted to 3% using sterile water for injection and used as a positive control. Composition of 3% Hemolok (sepgard) Gel: The test formulation used contained 3% feracrylum, 5% carbopol, 12.5% propylene glycol, 0.2% butylated hydroxyl 
    Yes! I am interested

    Erlotinib 150 Mg Tablet

    REQUEST CALLBACK

    Erlotinib 150 Mg Tablet
    Get Best Quote

    Thanks for Contacting Us.

    Approx. Rs 2,400 / BottleGet Latest Price

    Product Details:
    Minimum Order Quantity1 Bottle
    Packaging sizeBottle
    BrandErlotib 150Mg Tablets
    CompositionErlotinib
    ManufacturerIntas Pharmaceuticals
    Prescription/Non prescriptionPrescription
    FormTablet
    Shelf life15 Months

    Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better.

    Additional Information:

  • Item Code: 12333
  • Delivery Time: Depend on location
  • Yes! I am interested

    Nabota 100 Mg Injection

    REQUEST CALLBACK

    Nabota 100 Mg Injection
    • Nabota 100 Mg Injection
    • Nabota 100 Mg Injection
    • Nabota 100 Mg Injection
    Get Best Quote

    Thanks for Contacting Us.

    Approx. Rs 12,000 / VialGet Latest Price

    Product Details:
    Minimum Order Quantity1 Vial
    Prescription/Non prescriptionPrescription
    Treatmenttreatment of blepharospasm associated with dystonia
    Compositionbotulinum toxin type A.
    BrandDR Reddy
    Usage/ApplicationClinical
    Dose100Mg
    Packaging SizeVial
    Medicine TypeInjection
    Product TypeFinished Product
    GenderUnisex
    Form Of MedicineBotulinum Toxin
    Shelf Life24 Months

    Botulinum Toxin Type A (Nabota) is indicated for the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm, hemifacial spasm or VIIth nerve disorders in patients 12 years or older.
    Botulinum Toxin Type A (Nabota) is indicated for the correction of strabismus in patients 12 years or older.
    Botulinum Toxin Type A (Nabota) is indicated for the treatment of spasmodic torticollis (cervical dystonia) in adults.
    Botulinum Toxin Type A (Nabota) is indicated for the treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients, two years of age or older.
    Botulinum Toxin Type A (Nabota) is indicated for the temporary treatment of glabellar lines associated with corrugator and/or procerus muscle activity in adult patients below 65 years of age.
    Botulinum Toxin Type A (Nabota) is indicated in the management of focal spasticity, including the treatment of spasticity associated with stroke in adults.
    Botulinum Toxin Type A (Nabota) is indicated for the treatment of focal hyperhidrosis of the axilla.
    Botulinum Toxin Type A (Nabota) is indicated for the temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults.
    Botulinum Toxin Type A (Nabota) is indicated for the prophylaxis of headaches in adults with chronic migraine.
    Botulinum Toxin Type A (Nabota) is indicated for the treatment of urinary incontinence due to neurogenic detrusor overactivity e.g., spinal cord injury (SCI) or multiple sclerosis (MI) in adults.Dosage / Direction for UseBlepharospasm: Reconstituted Clostridium Botulinum Toxin Type A (see Table 1) is injected using a sterile, 27-30 gauge needle with or without electromyographic guidance.
    Initial Recommended Dose: 1.25-2.5 units in (0.05-0.1 mL volume at each site) injected into the medial and lateral orbicularis oculi of the upper lid and into the lateral orbicularis oculi of the lower lid.
    Injection placement may vary based on the patient's presentation. Avoiding injection near the levator palpebrae superioris may reduce the complication of ptosis. Avoiding medial lower lid injections and thereby reducing diffusion into the inferior oblique, may reduce the complication of diplopia. Ecchymosis occurs easily in the soft eyelid tissues. This can be prevented by applying pressure at the injection site immediately after the injection. The hazard of ectropion may be reduced by avoiding injection into the lower lid area.
    In general, the initial effect of the injections is seen within 3 days and reaches a peak at 1-2 weeks post-treatment. Each treatment lasts approximately 3 months, following which the procedure can be repeated indefinitely. At repeat-treatment sessions, the dose may be increased up to 2-fold if the response from the initial treatment is considered insufficient (usually defined as an effect that does not last longer than 2 months). However, there appears to be little benefit obtainable from injecting >5 units/site. The initial dose should not exceed 25 units/eye. Normally, no additional benefit is conferred by treating more frequently than every 3 months. It is rare for the effect to be permanent.
    In the management of blepharospasm, total dosing should not exceed 100 units every 12 weeks.

    Additional Information:

  • Item Code: 18609
  • Delivery Time: Depends On Location
  • Yes! I am interested

     
    X


    Explore More Products

    Contact via E-mail
    Contact via SMS
    SANTOSH CHAMOLI (Marketing Manager)
    D. Vijay Pharma Private Limited
    107, 1st Floor, Marathon Max, Goregaon Link Road, Mulund W
    Mumbai - 400080, Maharashtra, India
    Call Us: 
    Call Response Rate: 76%
    Share Us :



    Home  |   Profile   |  Our Products  |  Site Map  |   Contact Us

    © D. Vijay Pharma Private Limited. All Rights Reserved (Terms of Use)
    Developed and Managed by IndiaMART InterMESH Limited

    D. Vijay Pharma Private Limited